Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) – T4 N0-3 M0 or Any T N2-3 M0
Overview
– To establish maximum tolerated dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab in patients with locally advanced cancer in the anal region – To evaluate acute toxicity – To evaluate late toxicity – To evaluate response rate – To evaluate recurrence free survival – To evaluate overall survival
Full Title of Study: “Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) – T4 N0-3 M0 or Any T N2-3 M0”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: January 2020
Interventions
- Drug: Cetuximab
- Will be given weekly intravenously during study treatment.
- Drug: Mitomycin C
- Will be given intravenously twice together with 5-Fluoruracil during study treatment.
- Drug: 5-Fluoruracil
- Will be given intravenously twice together with Mitomycin C during study treatment
- Radiation: Radiotherapy
- Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
Arms, Groups and Cohorts
- Experimental: Cetuximab, Mitomycin C, Fluoruracil
Clinical Trial Outcome Measures
Primary Measures
- To establish maximum tolerable dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab and radiotherapy in patients with locally advanced cancer in the anal region
- Time Frame: Participating patients will be followed during the study period; 8 weeks.
Participating in This Clinical Trial
Inclusion Criteria
- Age over 18 years – Histologically or cytologically confirmed squamous cell cancer of the anal region (anal canal or anal margin or distal rectum) – Stage T2 (≥4 cm) – T4 N0-3 M0 or any T N2-3 M0 – ECOG performance status 0-1 – Hb > 100 g/L – ANC > 1.5 x 10 9/L – Platelets ≥ 100 x 10 9/L – Creatinine < 1.5 x ULN – Bilirubin < 1.5 x ULN – ALAT < 3.0 x ULN – Competent to comprehend, sign and date an approved informed consent form Exclusion Criteria:
- Previous pelvic irradiation – Previous chemotherapy for anal cancer – Previous malignancy within the last 5 years, except curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix uteri – Pregnant or nursing females or patients of child-bearing potential not using adequate methods of birth control – Patients with active infections or any other serious underlying medical condition, which would impair the ability of the patients to receive the protocol treatment – Known hypersensitivity to any of the components of the treatment – Clinically significant cardiovascular disease, e.g. cardiac failure (<12 months before treatment start), unstable angina, congestive heart failure, arrythmia requiring medication, or uncontrolled hypertension – Known positive test for hepatitis C virus, chronic active hepatitis B infection – Known HIV infection – Any other condition or therapy which in the investigator´s opinion may pose a risk to the patient or interfere with the study objectives – Any investigational agent within 30 days before enrolment – Surgery (excluding diagnostic biopsy or central venous catheter placement) and/or radiotherapy within 28 days prior to inclusion in the study
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Lund University Hospital
- Collaborator
- Merck Sharp & Dohme LLC
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Anders Johnsson, MD, PhD, Principal Investigator, Skåne University Hospital, Dept. of Oncology
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.